In one paragraphReview in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Yu-Zhang Liu *Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA, 15260, USA.
Hannah Rose Martin *Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, 15219, USA.
Brant P HaslerDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, 15219, USA.
Peter L FranzenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, 15219, USA.
Funding
Subject Management and BiobankingP50DA046346 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Daniel J. Buysse, Colleen A McClung · 2020 to 2026
$23.4MTranslational Research Training in Sleep MedicineT32HL082610 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Daniel J. Buysse, PETER L FRANZEN · 2007 to 2026
$5.8MGlial-mediated synaptic remodeling in drug addictionR01DA040620 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Yan Dong, ERIC J. NESTLER · 2016 to 2026
$5.3MRole of NPAS2 in the nucleus accumbens in drug addictionR01DA039865 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MCCLUNG, COLLEEN A · 2015 to 2024
$3.9MCocaine-induced adaptation in NMDA receptorsR37DA023206 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Yan Dong · 2018 to 2026
$3.9MSelective HDAC inhibition and therapeutic target genes: Identification of novel treatments for Bipolar DisorderR01MH106460 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MCCLUNG, COLLEEN A · 2016 to 2024
$3.6MCocaine-induced Adaptation in NMDA Receptors in Nucleus AccumbensR01DA023206 · NIDA · WASHINGTON STATE UNIVERSITY · PI DONG, YAN · 2008 to 2017
$3.0MMechanistic studies of alcohol-sleep interactionsR01AA028145 · NIAAA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HUANG, YANHUA H, TORREGROSSA, MARY M · 2019 to 2023
$2.0MMolecular rhythm alterations in human post-mortem brain associated with opioid use disorderR01DA051390 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOGAN, RYAN W, SENEY, MARIANNE L · 2020 to 2023
$1.9MSleep regulates drug relapse and addictionR01DA046491 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HUANG, YANHUA H · 2019 to 2023
$1.8MDeveloping a sleep EEG-based biomarker for drug relapse propensityR01DA057954 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Yanhua H Huang · 2024 to 2026
$1.6MRole of Striatal Molecular Rhythms in Sleep and Opioid Use DisorderR01DA062441 · NIDA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Ryan W Logan, Marianne L Seney · 2025 to 2026
$1.6MNHLBI NIH HHS T32 HL082610NIAAA NIH HHS R01 AA028145NIDA NIH HHS P50 DA046346NIDA NIH HHS R01 DA023206NIDA NIH HHS R01 DA039865NIDA NIH HHS R01 DA040620NIDA NIH HHS R01 DA046491NIDA NIH HHS R01 DA051390NIDA NIH HHS R01 DA057954NIDA NIH HHS R01 DA060868NIDA NIH HHS R01 DA061223NIDA NIH HHS R01 DA061227NIDA NIH HHS R01 DA062441NIDA NIH HHS R37 DA023206NIMH NIH HHS R01 MH106460NIMH NIH HHS RF1 MH106460U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL082610U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH106460U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) AA028145U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA023206U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA039865U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA040620U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA046346U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA046491U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA057954U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA058729U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA060868U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA061227U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA062441
6 · The paper itselfAbstract
The recent decade has seen an increasing recognition of the importance of sleep in substance use disorders (SUD) in both research and clinical settings. Not only is sleep disturbance a common comorbidity in SUD, but it may provide a causal link and druggable targets for complementary treatment. The interpersonal variation in sleep also provides opportunities for developing biomarkers and individualized medicine. This review is focused on the key neurotransmitter and neuromodulator systems through which sleep loss may bias reward seeking, increasing the risks for initial drug exposure as well as relapse after drug withdrawal. The review summarizes sleep changes following acute or long-term drug exposure and withdrawal, and current understanding of sleep-mediated regulation of glutamatergic, dopaminergic, and peptidergic transmissions importantly indicated in SUD research.
Indexed as
Drug-Seeking BehaviorSleepSubstance-Related DisordersAnimalsHumansNeurotransmitter AgentsRecurrenceRewardSleep Wake DisordersSubstance Withdrawal SyndromeNeurotransmitter Agents
Identifiers
PMID41620581
PMCPMC12990087
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390